journal article·2018-11-12Open access

Quantitative proteomic analysis to the first commercialized liposomal paclitaxel nano-platform Lipusu revealed the molecular mechanism of the enhanced anti-tumor effect

Minzhi Zhao, Haiyun Li, Linyang Fan, Yan Ma, He Gong, Wenjia Lai, Qiaojun Fang, Zhiyuan Hu

Abstract

The first nano-platform commercialized as a drug delivery system was a liposomal formulation. The application of liposome technology resolved the issues of paclitaxel (PTX) insolubility and eliminated the use of solvents causing toxic side-effects, which enabled to apply higher drug doses leading to an enhanced drug efficacy. The growth-inhibitory activity of liposome-encapsulated PTX was retained in vitro against a variety of tumor cell. To investigate the drug efficacy in the system biological level, quantitative proteomic analysis was employed to study the molecular mechanism of the anti-tumor effect of Lipusu® (lip) compared with PTX on lung cancer cell A549. The functions of the differential expressed proteins were correlated to the negative effect to cell proliferation due to regulation of hippo pathway and prolonged cell cycle, as well as inhibitory cell exocytosis, which would cause the aggregation of free PTX. This investigation focused on the direct biological effect of lip to cancer cells. It was different from pharmaceutical issues about drug exposure, delivery and distribution which were widely investigated in other traditional studies. It was the first study about the drug effect of lip from the global molecular biological aspect.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Hedgehog Signaling Pathway Studies · Hippo pathway signaling and YAP/TAZ · Cell Adhesion Molecules Research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

CAS Key Laboratory of Standardization and Measurement for Nanotechnology, CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology of China

University of Chinese Academy of Sciences

School of Life Science, Beijing Institute of Technology

Sino-Danish College, University of Chinese Academy of Sciences

Center for Neuroscience Research, School of Basic Medical Sciences, Fujian Medical University

Funding

National Natural Science Foundation of China · ‘Strategic Priority Research Program’ · Chinese Academy of Sciences · Beijing Municipal Science and Technology Project · Beijing Talents Fund · Beijing Municipal Natural Science Foundation

References (30)

Show source-provided references
1. 10.3322/caac.2116610.3322/caac.21166 ↗
2. 10.1056/NEJMoa01195410.1056/NEJMoa011954 ↗
3. 10.1016/j.lungcan.2005.06.01010.1016/j.lungcan.2005.06.010 ↗
4. 10.1016/S0959-8049(01)00171-X10.1016/S0959-8049(01)00171-X ↗
5. 10.1023/A:101061863273810.1023/A:1010618632738 ↗
6. Xu Q, Trissel LA, Martinez JF. Stability of paclitaxel in 5% dextrose injection or 0.9% sodium chloride injection at 4, 22, or 32 degrees C. Am J Hosp Pharm. 1994;51:3058–3060.
7. 10.1016/j.ijpharm.2017.05.01610.1016/j.ijpharm.2017.05.016 ↗
8. Cabanes A, Briggs KE, Gokhale PC, et al. Comparative in vivo studies with paclitaxel and liposome-encapsulated paclitaxel. Int J Oncol. 1998;12:1035.
9. 10.1002/jps.260084120410.1002/jps.2600841204 ↗
10. 10.3109/0265204900902183210.3109/02652049009021832 ↗
11. 10.1016/0304-3835(96)04380-710.1016/0304-3835(96)04380-7 ↗
12. 10.1023/A:101899411159410.1023/A:1018994111594 ↗
13. 10.1016/j.jconrel.2012.09.00610.1016/j.jconrel.2012.09.006 ↗
14. 10.1016/j.biopha.2008.10.00110.1016/j.biopha.2008.10.001 ↗
15. 10.1016/j.ejca.2010.02.00210.1016/j.ejca.2010.02.002 ↗
16. 10.1002/jps.2216910.1002/jps.22169 ↗
17. 10.1016/j.jpor.2015.10.00110.1016/j.jpor.2015.10.001 ↗
18. 10.1021/nn402330b10.1021/nn402330b ↗
19. 10.1158/0008-5472.CAN-07-293010.1158/0008-5472.CAN-07-2930 ↗
20. 10.1016/j.jmb.2012.12.00910.1016/j.jmb.2012.12.009 ↗
21. 10.1093/carcin/bgs14110.1093/carcin/bgs141 ↗
22. 10.1007/BF0187057210.1007/BF01870572 ↗
23. 10.1111/j.1749-6632.1985.tb14862.x10.1111/j.1749-6632.1985.tb14862.x ↗
24. 10.1007/BF0023574110.1007/BF00235741 ↗
25. 10.1152/ajplung.00021.200410.1152/ajplung.00021.2004 ↗
26. 10.18632/oncotarget.2024010.18632/oncotarget.20240 ↗
27. 10.1073/pnas.081023210510.1073/pnas.0810232105 ↗
28. 10.3233/CBM-13033610.3233/CBM-130336 ↗
29. 10.1074/jbc.M110.21570710.1074/jbc.M110.215707 ↗
30. 10.1101/gad.190921010.1101/gad.1909210 ↗